Aqtual: Over $30 Million Raised For Precision Medicine
By Amit Chowdhry ● Jul 15, 2025
Aqtual, a precision medicine company developing products for chronic diseases and oncology, has raised $31 million in Series B funding. The oversubscribed round saw new investors, including Bold Capital and Bold Longevity Growth Fund, join existing investors Genoa Ventures, Manta Ray Ventures, and Yu Galaxy. A strategic diagnostics investor also contributed, boosting Aqtual's ability to advance its novel active chromatin cell-free DNA (cfDNA) platform towards commercializing its first flagship product: a therapy response prediction test for rheumatoid arthritis (RA).